Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The Chronic Kidney Disease Screening and Quality Use of Medicines (CKD-QUM) trial, conducted through community pharmacies located in kidney failure hotspot areas, aimed to improve CKD detection and optimise medication use in Australia. In this analysis, we describe participants’ baseline characteristics and compare CKD risk factors with estimates from the National Health Measures Survey (NHMS, 2011–2012).
Eligible participants were aged 35–74 years and had one or more CKD risk factors. The QKidney® risk tool was used in combination with blood pressure (BP) levels to stratify patients’ 5-year CKD risk as low, moderate or high. Point-of-care (POC) testing of serum creatinine concentration to estimate the glomerular filtration rate (eGFR) was performed in the intervention arm among participants at moderate-to-high risk. The prevalence of CKD risk factors and reduced kidney function was compared with NHMS data. Data were organised in Excel and analysed in SPSS (version 31 for Windows) using descriptive statistics.
Of the 1,485 participants recruited over two years, 1,193 were included in this analysis (552 [46.3%] in the intervention arm and 641 [53.7%] in the control arm). Most participants were from metropolitan areas (61%) and were female (56.2%), while 3.5% identified as First Nations people. The mean (±SD) age was 61.3±9.8 years and the mean (±SD) BMI was 30.5±6.6 kg/m2. Compared with NHMS estimates, trial participants had a significantly higher prevalence of being overweight/obese (82%, 95% CI 80–84 vs 60.5%, 95% CI 56–65), hypertension (70%, 95% CI 68–73 vs 34.1%, 95% CI 29.8–38.4) and diabetes (38%, 95% CI 35–40 vs 16.2%, 95% CI 13.5–18.9). Overall, 68% of trial participants were at moderate-to-high risk of CKD (58.6% by QKidney®; 30.5% by BP). Among the 400 moderate-to-high risk participants in the intervention arm, 84 (21%) had reduced kidney function (eGFR <60 mL/min/1.73 m2) on POC testing—substantially higher than the national estimate (5.2%, NHMS 2022–2024).
This analysis demonstrated that targeted screening in community pharmacies effectively identified patients at risk of developing CKD, providing an opportunity to enhance early detection and implement interventions such as optimising medication use through pharmacist counselling.
Disclosure: This abstract has also been submitted and accepted for oral presentation at the Australasian Pharmaceutical Science Association (APSA) Annual Conference, to be held in Adelaide, Australia, from 7 to 10 December 2025.
